EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Targeting CD39 as a Therapeutic for Cancer Immunotherapy

Zhongliang Li, Weiguo Xu, Hang Fai Kwok iD

Expert Reviews in Molecular Medicine · 2026 · 28

DOI: 10.1017/erm.2026.10033 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Expert Reviews in Molecular Medicine, online erschienen am 26.01.2026. Verfasst von Zhongliang Li und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, Faculty of Health Sciences, https://ror.org/01r4q9n85University of Macau, Avenida da Universidade, Taipa, Macao an…. Hauptthemen laut MEDLINE: Apyrase, Neoplasms, Immunotherapy. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 95 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundo para o Desenvolvimento das Ciências e da Tecnologia, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CD39 plays a pivotal role in the ATP-to-adenosine signalling pathway, serving as a critical mediator of immune suppression within the tumour microenvironment. Increasing preclinical evidence indicates that its inhibition can restore antitumour immunity and improve the efficacy of established treatments. In this review, we summarise the biology of CD39, its role in shaping the immunosuppressive tumour microenvironment, and therapeutic strategies currently under development. We also discuss early clinical progress and safety considerations, along with major challenges and future perspectives. Targeting CD39 represents a promising strategy to overcome tumour-induced immunosuppression and ongoing advances in therapeutic development could usher in next-generation immunotherapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ApyraseNeoplasmsImmunotherapyHumansTumor MicroenvironmentAnimalsSignal TransductionMolecular Targeted Therapy

Stichwörter der Autor:innen

CD39immune evasionimmune suppressionimmunotherapytumour microenvironment

Substanzen

ApyraseENTPD1 protein, human

Autor:innen und Institutionen

  • Department of Biomedical Sciences, Faculty of Health Sciences, https://ror.org/01r4q9n85University of Macau, Avenida da Universidade, Taipa, Macao and Zhuhai People's Hospital Centre for Precision Medicine, Zhuhai Clini…
  • Department of Cerebrovascular Disease, Center of Intervention Radiology,https://ror.org/01k1x3b35Zhuhai People's Hospital (The Affiliated Hospital of Beijing Institute of Technology, Zhuhai Clinical Medical College of J…
  • Department of Biomedical Sciences, Faculty of Health Sciences, https://ror.org/01r4q9n85University of Macau, Avenida de Universidade, Taipa, Macao.

ORCID-Profile: Hang Fai Kwok

Förderung

  • Fundo para o Desenvolvimento das Ciências e da Tecnologia
  • National Natural Science Foundation of China

Zitieren

APA

Li, Z., Xu, W., & Kwok, H. F. (2026). Targeting CD39 as a Therapeutic for Cancer Immunotherapy. Expert Reviews in Molecular Medicine, 28. https://doi.org/10.1017/erm.2026.10033

Vancouver

Li Z, Xu W, Kwok HF. Targeting CD39 as a Therapeutic for Cancer Immunotherapy. Expert Reviews in Molecular Medicine. 2026;28. doi:10.1017/erm.2026.10033

BibTeX
@article{Li2026,
  author = {Li, Zhongliang and Xu, Weiguo and Kwok, Hang Fai},
  title = {Targeting CD39 as a Therapeutic for Cancer Immunotherapy},
  journal = {Expert Reviews in Molecular Medicine},
  year = {2026},
  volume = {28},
  doi = {10.1017/erm.2026.10033}
}
Kostenlos starten →